To address the challenges facing today’s life sciences industry, existing LIMS and ELN solutions are not sufficient. Digitalization initiatives are front and center in 2020, to ensure processes and data are standardized, easily accessible, and that products get to market quickly. Learn how the latest advancements in BIOVIA ONE Lab are helping the top pharma companies achieve their goals.
Today’s Life Science companies are facing major challenges to their continued operations and profitability as they deal with a shifting and changing workplace. Add in the existing challenges of patent expirations, low R&D productivity, increased competition and decreasing margins, as well as non-optimized processes and compliance pressure, and the result is unprecedented cost pressure and uncompetitive cycle times.
In this environment, existing LIMS and ELNs are not enough, as paper and manual processes are still a daily reality. Today's challenges require true digital continuity, holistic solutions, and data standards for compliance, all in the cloud. We are going to demonstrate why digital continuity is so important to succeed in 2020 and beyond.
BIOVIA ONE Lab is the only system in the world that provides theste end-to-end capabilities, along with the underlying infrastructure and ability to implement industry standards. The top pharma companies and others in science-based industries have realized this, and are implementing BIOVIA ONE Lab to transform their operations.
In this webinar we delve into the enhancements to BIOVIA ONE Lab in 2020, including features for better scalability, usability, increased compliance, and lower total cost of ownership.
Presented by: